Cargando…

Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with high rates of recurrence and metastasis. There are no standard treatment options available for patients with recurrence and metastases. The case of a 61-year-old male with SDC of the left parotid gland is presented in this study....

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Yongfei, Wang, Panpan, Wan, Xi, Xu, Liping, Gong, Yi, Zhang, Weihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169051/ https://www.ncbi.nlm.nih.gov/pubmed/34093024 http://dx.doi.org/10.2147/OTT.S304900

Ejemplares similares

Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands
por: Boon, Eline, et al.
Publicado: (2017)

Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy
por: van Boxtel, Wim, et al.
Publicado: (2019)

Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report
por: Wasano, Koichiro, et al.
Publicado: (2018)

Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
por: van Boxtel, Wim, et al.
Publicado: (2019)

Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma
por: Kawakita, Daisuke, et al.
Publicado: (2022)

Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report
por: Rösch, Manuel, et al.
Publicado: (2023)

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study
por: Viscuse, Paul V., et al.
Publicado: (2019)

Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
por: Lassche, Gerben, et al.
Publicado: (2021)

Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2
por: Ito, Hiroko, et al.
Publicado: (2019)

A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma
por: Fushimi, C, et al.
Publicado: (2018)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Androgen Receptor Signaling in Salivary Gland Cancer
por: Dalin, Martin G., et al.
Publicado: (2017)

HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients
por: Cavalieri, Stefano, et al.
Publicado: (2023)

Androgen receptor-positive ductal adenocarcinoma of the nasolacrimal duct: A case report
por: Park, In Ah, et al.
Publicado: (2016)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Androgen Receptor Roles in Insulin Resistance and Obesity in Males: The Linkage of Androgen-Deprivation Therapy to Metabolic Syndrome
por: Yu, I-Chen, et al.
Publicado: (2014)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells
por: Levina, Elina, et al.
Publicado: (2015)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer
por: Jung, Jaeyoon, et al.
Publicado: (2015)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
por: Fiorica, Francesco, et al.
Publicado: (2022)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

What Is Your Choice for Androgen Deprivation Therapy in Metastatic Prostate Carcinoma: Surgical or Medical?
por: Salih Semiz, Huseyin, et al.
Publicado: (2022)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Assessing salivary matrix metalloproteinase‐8 in prostate cancer patients undergoing androgen deprivation therapy
por: Memon, Maaz A., et al.
Publicado: (2022)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation
por: Duan, Lingling, et al.
Publicado: (2019)

Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ifnn6ut19ljg0e28d4rqnk673b